Wynn Capital LLC Buys 103 Shares of Amgen Inc. (NASDAQ:AMGN)

Wynn Capital LLC increased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 1.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,528 shares of the medical research company’s stock after buying an additional 103 shares during the quarter. Amgen accounts for about 1.4% of Wynn Capital LLC’s investment portfolio, making the stock its 18th largest position. Wynn Capital LLC’s holdings in Amgen were worth $2,103,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Hershey Financial Advisers LLC acquired a new stake in Amgen during the 2nd quarter valued at $30,000. nVerses Capital LLC acquired a new stake in Amgen during the 2nd quarter valued at $31,000. Bbjs Financial Advisors LLC acquired a new stake in Amgen during the 2nd quarter valued at $33,000. Matrix Trust Co acquired a new stake in Amgen during the 3rd quarter valued at $36,000. Finally, FSA Wealth Management LLC increased its stake in shares of Amgen by 182.0% in the 1st quarter. FSA Wealth Management LLC now owns 141 shares of the medical research company’s stock valued at $40,000 after buying an additional 91 shares during the period. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Price Performance

NASDAQ:AMGN opened at $328.35 on Friday. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.89 and a current ratio of 1.26. The stock’s 50-day simple moving average is $326.06 and its 200 day simple moving average is $310.55. The company has a market cap of $176.43 billion, a P/E ratio of 56.51, a P/E/G ratio of 2.86 and a beta of 0.61. Amgen Inc. has a 52-week low of $249.70 and a 52-week high of $346.85.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). The company had revenue of $8.39 billion during the quarter, compared to analyst estimates of $8.35 billion. Amgen had a net margin of 10.12% and a return on equity of 161.72%. Amgen’s revenue was up 20.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $5.00 EPS. As a group, sell-side analysts forecast that Amgen Inc. will post 19.49 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, August 6th. Shareholders of record on Friday, August 16th were given a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a yield of 2.74%. The ex-dividend date was Friday, August 16th. Amgen’s dividend payout ratio (DPR) is presently 154.91%.

Wall Street Analyst Weigh In

Several research firms have recently commented on AMGN. Robert W. Baird reissued an “underperform” rating and issued a $215.00 target price on shares of Amgen in a research note on Wednesday, September 25th. Morgan Stanley lowered their target price on Amgen from $310.00 to $303.00 and set an “equal weight” rating for the company in a research note on Thursday, July 11th. Argus lifted their target price on Amgen from $300.00 to $340.00 and gave the company a “buy” rating in a research note on Thursday, June 27th. Wells Fargo & Company lowered Amgen from an “overweight” rating to an “equal weight” rating and raised their price target for the stock from $320.00 to $335.00 in a research report on Wednesday, August 7th. Finally, TD Cowen raised their price target on Amgen from $360.00 to $381.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $326.30.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.